Bioventix PLC creates, manufactures, and supplies sheep monoclonal antibodies (SMAs) for diagnostic applications worldwide. The company offers a portfolio of purified SMAs for thyroid, vitamin D, cardiac, drugs of abuse, fertility, oncology, and miscellaneous indications; Pyrene 1-hydroxypyrene glucuronide (HOP-G) ELISA kit to monitor human exposure to industrial pollutants; and Pyrene (HOP-G) lateral flow kits for monitoring of at-risk individuals without laboratory equipment. It also provides contract SMAs services; and industrial and environmental biomonitoring platform, which reduces the time between sampling and results. Bioventix PLC was incorporated in 2003 and is based in Farnham, United Kingdom.
Metrics to compare | BVXP | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipBVXPPeersSector | |
---|---|---|---|---|
P/E Ratio | 15.3x | −6.8x | −0.6x | |
PEG Ratio | −1.65 | 0.09 | 0.00 | |
Price/Book | 10.7x | 3.9x | 2.6x | |
Price / LTM Sales | 8.8x | 11.0x | 3.3x | |
Upside (Analyst Target) | 95.7% | 89.0% | 40.2% | |
Fair Value Upside | Unlock | 14.4% | 5.1% | Unlock |